AF Association News & Events
FibriCheck honoured to support Arrhythmia Alliance World Heart Week 2021
FibriCheck — the world’s first medically certified app for the timely detection of heart rhythm disorders such as atrial fibrillation using just a smartphone or smartwatch — is supporting Arrhythmia Alliance World Heart Rhythm Week (7–13 June). WHRW is an annual event that seeks to raise awareness of arrhythmias and, this year, a core message is “Listen To Your Heart”. The Listen To Your Heart campaign highlights important statistics about arrhythmias, such as that approximately half a million people in the UK are unaware that they have the arrhythmia (heart rhythm disorder) atrial fibrillation (AF)
AF is the most common type of arrhythmia and is a major cause of stroke — without appropriate therapy, a person with AF is five times more likely to have a stroke than someone without AF. However, AF is often asymptomatic (without symptoms), and people sometimes do not discover that they have AF until they have an AF-related stroke. Therefore, the charity Arrhythmia Alliance (and its sister charity AF Association) run the “Know Your Pulse” campaign to raise awareness that an irregular pulse is a potential sign of AF. If you DETECT an irregular pulse, with a pulse check, and are subsequently diagnosed with AF, you can receive anti-coagulation to protect against AF-related strokes. Arrhythmia Alliance and AF Association, thus, say “Know Your Pulse to Know Your Heart Rhythm — it Could Save Your Life”.
In its 2021 AF White Paper — Put People First, AF Association say that any contact with a person aged ≥65 is an opportunity to DETECT AF, which can be in the form of a medical contact with a healthcare professional or in a non-healthcare community setting. However, because of the pandemic and the need to social distance, many of these opportunities have not been available. Potentially, this means that both the number of people with undiagnosed AF and the number of AF-related strokes have increased — if people have not been diagnosed, they are not receiving anti-coagulation.
To address this challenge, a press release reports, FibriCheck is supporting and empowering people to DETECT AF at home with their smartphone. As a CE certified medical software solution, FibirCheck transforms an everyday smartphone into a medical device — delivering a diagnostic grade analytics report that can be shared with a healthcare provider for follow up, in cases of suspected irregularities.
Detecting AF with FibriCheck is as easy as downloading the app and placing a finger on the camera of a smartphone for 60 seconds. The app provides instant analysis, and where irregularities are detected, the results are reviewed by medical professionals. Affording peace of mind and ensuring confidence in the results for treating healthcare professionals. This approach not only supports safe, shared, and engaged self-care, but evidence informed decision-making for the next steps in the healthcare journey.
Mrs Trudie Lobban, MBE, Founder and CEO of Arrhythmia Alliance, says: “Arrhythmia Alliance has always encouraged people to get into the habit of regularly checking their pulse because it could save their life. We believe technologies, like FibriCheck, are a great way to do this. They are simple to use and allow a person to wirelessly send information to a healthcare professional without the need to travel to a clinic.”
Bieke Van Gorp, FibriCheck Co-Founder and NIA Fellow: “AF is a silent killer because episodes can be mild, infrequent, even symptomless in the early onset. Unsurprisingly many people are unaware they are even at-risk, often dismissing occasional palpitations until it’s too late. By providing an on-demand option to the public, this year’s World Heart Rhythm Week aims to improve population health and reduce the barriers to access by meeting people where they are. We are proud to partner with Arrhythmia Alliance to realise a future where avoidable cardiac deaths are a thing of the past. Improved condition awareness and early detection will go a long way in reducing AF mortality rates as well as the individual burden and societal impacts associated with its comorbid complications.”